Xcout IntelNavion Neurosciences Inc.
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Subscribe to see Navion Neurosciences Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Navion Neurosciences Inc. at a glance
Navion Neurosciences Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $10.8M in September 2026. Xcout tracks 8 named people at Navion Neurosciences Inc., including Michael Innes (Chief Business Officer).
Navion Neurosciences Inc. leadership
- Michael InnesChief Business Officer
- Andrew KrouseFounder, President & Chief Executive Officer
- Michelle HigginFounder & Chief Operating Officer
- Manoj PatelFounder & Chief Scientific Officer
- Thomas RichardsonFounder & Director of Chemistry
- Andrew J KrouseExecutive Officer
2 more named people on record for Navion Neurosciences Inc., with roles, board committees and tenure — see the full roster →
Navion Neurosciences Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10.8M | 6 named | |
| SEC Form D filing | $1.9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Navion Neurosciences Inc. news
- FundingPrivate placement (Form D)
Investors
Navion Neurosciences Inc. competitors
A few of Navion Neurosciences Inc.'s closest competitors — see the full list of competitors and alternatives →
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
NanoVation Therapeutics is a platform developer headquartered in Vancouver, British Columbia, that partners with leading pharmaceutical and biotech companies to enable genetic medicines.
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Get Navion Neurosciences Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Navion Neurosciences Inc. in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access